|
US20030133939A1
(en)
|
2001-01-17 |
2003-07-17 |
Genecraft, Inc. |
Binding domain-immunoglobulin fusion proteins
|
|
US7754208B2
(en)
|
2001-01-17 |
2010-07-13 |
Trubion Pharmaceuticals, Inc. |
Binding domain-immunoglobulin fusion proteins
|
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
|
GB0423653D0
(en)
*
|
2004-10-25 |
2004-11-24 |
Piramed Ltd |
Pharmaceutical compounds
|
|
DK1850874T3
(da)
|
2005-02-23 |
2013-11-11 |
Genentech Inc |
Forlængelse af tid til sygdomsprogression eller overlevelse for ovariecancer ved anvendelse af pertuzumab
|
|
ES2460517T3
(es)
|
2005-07-25 |
2014-05-13 |
Emergent Product Development Seattle, Llc |
Reducción de células b mediante el uso de moléculas de unión específica a cd37 y de unión específica a cd20
|
|
EP2418223A3
(en)
|
2006-06-12 |
2013-01-16 |
Emergent Product Development Seattle, LLC |
Single-chain multivalent binding proteins with effector function
|
|
BRPI0808418A2
(pt)
|
2007-03-02 |
2014-07-22 |
Genentech, Inc |
Predição de resposta a um inibidor de her
|
|
GB0721095D0
(en)
*
|
2007-10-26 |
2007-12-05 |
Piramed Ltd |
Pharmaceutical compounds
|
|
TWI472339B
(zh)
|
2008-01-30 |
2015-02-11 |
Genentech Inc |
包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
|
|
HUE035184T2
(en)
*
|
2008-03-18 |
2018-05-02 |
Genentech Inc |
Combinations of an anti-HER2 antibody-drug conjugate and docetaxel
|
|
PT2132228E
(pt)
|
2008-04-11 |
2011-10-11 |
Emergent Product Dev Seattle |
Imunoterapia de cd37 e sua combinação com um quimioterápico bifuncional
|
|
BRPI0812682A2
(pt)
|
2008-06-16 |
2010-06-22 |
Genentech Inc |
tratamento de cáncer de mama metastático
|
|
TWI378933B
(en)
|
2008-10-14 |
2012-12-11 |
Daiichi Sankyo Co Ltd |
Morpholinopurine derivatives
|
|
DK2385832T3
(en)
|
2009-01-08 |
2015-09-21 |
Curis Inc |
Phosphoinositid-3-kinase-inhibitorer med en zink-bindingsdel
|
|
BRPI1006189A2
(pt)
|
2009-03-12 |
2020-08-18 |
Genentech Inc |
uso de uma combinação terapêutica, formulação farmacêutica, artigo de manufatura, produto, método para determinar compostos a serem utilizados em combinação para o tratamento de uma malignidade hematopoiética e método para selecionar compostos a serem utilizados em combinação para o tratamento de câncer
|
|
SG10201405568UA
(en)
*
|
2009-09-08 |
2014-11-27 |
Hoffmann La Roche |
4-substituted pyridin-3-yl-carboxamide compounds and methods of use
|
|
WO2011031896A2
(en)
*
|
2009-09-09 |
2011-03-17 |
Avila Therapeutics, Inc. |
Pi3 kinase inhibitors and uses thereof
|
|
US20110086837A1
(en)
*
|
2009-10-12 |
2011-04-14 |
Genentech, Inc. |
Combinations of a pi3k inhibitor and a mek inhibitor
|
|
WO2011069074A2
(en)
*
|
2009-12-04 |
2011-06-09 |
Genentech, Inc. |
Methods of treating metastatic breast cancer with trastuzumab-mcc-dm1
|
|
PH12012501361A1
(en)
|
2009-12-31 |
2012-10-22 |
Centro Nac De Investigaciones Oncologicas Cnio |
Tricyclic compounds for use as kinase inhibitors
|
|
UY33236A
(es)
|
2010-02-25 |
2011-09-30 |
Novartis Ag |
Inhibidores dimericos de las iap
|
|
BR112012024585A2
(pt)
|
2010-03-30 |
2016-05-31 |
Novartis Ag |
inibidores de pkc para o tratamento de linfomade células b tendo sinalização do receptor de células b ativas crônicas
|
|
CN103038643A
(zh)
*
|
2010-04-16 |
2013-04-10 |
基因泰克公司 |
作为pi3k/akt激酶途径抑制剂效能的预测性生物标记的foxo3a
|
|
US9586996B2
(en)
|
2010-04-30 |
2017-03-07 |
Esperance Pharmaceuticals, Inc. |
Lytic-peptide-Her2/neu (human epidermal growth factor receptor 2) ligand conjugates and methods of use
|
|
EP2580320B1
(en)
|
2010-06-14 |
2018-08-01 |
The Scripps Research Institute |
Reprogramming of cells to a new fate
|
|
PL2606070T3
(pl)
|
2010-08-20 |
2017-06-30 |
Novartis Ag |
Przeciwciała dla receptora epidermalnego czynnika wzrostu 3 (her3)
|
|
AU2011308906B2
(en)
*
|
2010-10-01 |
2016-06-16 |
Biogen Ma Inc. |
Interferon-beta for use as monotherapy or in combination with other cancer therapies
|
|
UY33794A
(es)
|
2010-12-13 |
2012-07-31 |
Novartis Ag |
Inhibidores diméricos de las iap
|
|
JP2014501235A
(ja)
|
2010-12-13 |
2014-01-20 |
ノバルティス アーゲー |
二量体ｉａｐ阻害剤
|
|
WO2012098387A1
(en)
|
2011-01-18 |
2012-07-26 |
Centro Nacional De Investigaciones Oncológicas (Cnio) |
6, 7-ring-fused triazolo [4, 3 - b] pyridazine derivatives as pim inhibitors
|
|
PL3111938T3
(pl)
*
|
2011-04-01 |
2019-09-30 |
Curis, Inc. |
Inhibitor 3-kinazy fosfoinozytydowej z grupą wiążącą cynk
|
|
CN103841976A
(zh)
|
2011-04-01 |
2014-06-04 |
基因泰克公司 |
Akt和mek抑制剂化合物的组合及其使用方法
|
|
AR086647A1
(es)
*
|
2011-06-03 |
2014-01-15 |
Hoffmann La Roche |
Metodos para tratar el mesotelioma con un compuesto inhibidor de la pi3k
|
|
MX2014000536A
(es)
|
2011-07-13 |
2014-12-05 |
Novartis Ag |
Compuestos de 4-piperidinilo para usarse como inhibidores de tanquirasa.
|
|
US9181266B2
(en)
|
2011-07-13 |
2015-11-10 |
Novartis Ag |
2-piperidin-1-yl-acetamide compounds for use as tankyrase inhibitors
|
|
WO2013010092A1
(en)
|
2011-07-13 |
2013-01-17 |
Novartis Ag |
4-oxo-3,5,7,8-tetrahydro-4h-pyrano {4,3-d} pyrminidinyl compounds for use as tankyrase inhibitors
|
|
PL3409278T3
(pl)
|
2011-07-21 |
2021-02-22 |
Sumitomo Pharma Oncology, Inc. |
Heterocykliczne inhibitory kinazy białkowej
|
|
WO2013019620A2
(en)
*
|
2011-07-29 |
2013-02-07 |
Glaxosmithkline Llc |
Method of treating cancer using combination of braf inhibitor, mek inhibitor, and anti-ctla-4 antibody
|
|
JP6062442B2
(ja)
|
2011-10-13 |
2017-01-18 |
ジェネンテック， インコーポレイテッド |
薬剤誘発性低酸症の治療
|
|
MY194408A
(en)
|
2011-10-14 |
2022-11-30 |
Genentech Inc |
Uses for and Article of Manufacture Including Her2 Dimerization Inhibitor Pertuzumab
|
|
EP2776837A4
(en)
*
|
2011-11-11 |
2015-05-20 |
Intellikine Llc |
COMBINATION OF KINASEINHIBITORS AND THEIR USE
|
|
MX2014006736A
(es)
|
2011-12-05 |
2014-08-29 |
Novartis Ag |
Derivados de urea ciclicos como antagonistas de los receptores de androgeno.
|
|
AU2012349735B2
(en)
|
2011-12-05 |
2016-05-19 |
Novartis Ag |
Antibodies for epidermal growth factor receptor 3 (HER3)
|
|
US20130273029A1
(en)
|
2011-12-05 |
2013-10-17 |
Novartis Ag |
Antibodies for epidermal growth factor receptor 3 (her3) directed to domain ii of her3
|
|
CA2860676A1
(en)
|
2012-01-09 |
2013-07-18 |
Novartis Ag |
Organic compositions to treat beta-catenin-related diseases
|
|
KR101915942B1
(ko)
|
2012-06-08 |
2018-11-06 |
에프. 호프만-라 로슈 아게 |
암의 치료를 위한 포스포이노시타이드 3 키나제 억제제 화합물 및 화학치료제의 돌연변이체 선택성 및 조합물
|
|
WO2013192367A1
(en)
|
2012-06-22 |
2013-12-27 |
Novartis Ag |
Neuroendocrine tumor treatment
|
|
KR101698283B1
(ko)
|
2012-10-10 |
2017-01-19 |
에프. 호프만-라 로슈 아게 |
티에노피리미딘 화합물의 제조 방법
|
|
WO2014062838A2
(en)
|
2012-10-16 |
2014-04-24 |
Tolero Pharmaceuticals, Inc. |
Pkm2 modulators and methods for their use
|
|
MX2015007054A
(es)
*
|
2012-12-07 |
2016-01-12 |
Gen Hospital Corp |
Combinaciones de un compuesto inhibidor de pi3k/akt con un compuesto inhibidor de her3/egfr, y métodos de uso.
|
|
EP2958907B1
(en)
|
2013-02-19 |
2018-02-28 |
Novartis AG |
Benzothiophene derivatives and compositions thereof as selective estrogen receptor degraders
|
|
PL2958943T3
(pl)
|
2013-02-20 |
2020-04-30 |
The Trustees Of The University Of Pennsylvania |
Leczenie nowotworu złośliwego za pomocą humanizowanego chimerycznego receptora antygenowego anty-egfrviii
|
|
US9498532B2
(en)
|
2013-03-13 |
2016-11-22 |
Novartis Ag |
Antibody drug conjugates
|
|
RU2693480C2
(ru)
|
2013-03-14 |
2019-07-03 |
Толеро Фармасьютикалз, Инк. |
Ингибиторы jak2 и alk2 и способы их использования
|
|
CN105007950B
(zh)
|
2013-03-15 |
2019-01-15 |
诺华股份有限公司 |
抗体药物缀合物
|
|
TWI554284B
(zh)
|
2013-04-16 |
2016-10-21 |
建南德克公司 |
帕妥珠單抗（ｐｅｒｔｕｚｕｍａｂ）變體及其評估
|
|
WO2015092634A1
(en)
|
2013-12-16 |
2015-06-25 |
Novartis Ag |
1,2,3,4-tetrahydroisoquinoline compounds and compositions as selective estrogen receptor antagonists and degraders
|
|
JO3517B1
(ar)
|
2014-01-17 |
2020-07-05 |
Novartis Ag |
ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
|
|
US10093646B2
(en)
|
2014-01-17 |
2018-10-09 |
Novartis Ag |
1-pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and compositions thereof for inhibiting the activity of SHP2
|
|
ES2699354T3
(es)
|
2014-01-17 |
2019-02-08 |
Novartis Ag |
Derivados de 1-(triazin-3-il/piridazin-3-il)-piper(-azin)idina y composiciones de las mismas para inhibir la actividad de SHP2
|
|
RU2020120593A
(ru)
|
2014-04-25 |
2020-09-01 |
Дженентек, Инк. |
Способы лечения раннего рака молочной железы трастузумабом-mcc-dm1 и пертузумабом
|
|
CN106456776A
(zh)
|
2014-05-21 |
2017-02-22 |
豪夫迈·罗氏有限公司 |
用PI3K抑制剂Pictilisib治疗PR阳性腔性A乳腺癌的方法
|
|
EP3392348A3
(en)
*
|
2014-06-16 |
2018-11-21 |
Worldwide Innovative Network |
Method for selecting personalized tri-therapy for cancer treatment
|
|
CN107257691B
(zh)
|
2014-07-16 |
2021-09-21 |
达娜-法勃肿瘤研究所公司 |
低级别浆液性卵巢癌中的her3抑制
|
|
WO2016020791A1
(en)
|
2014-08-05 |
2016-02-11 |
Novartis Ag |
Ckit antibody drug conjugates
|
|
EA201790334A1
(ru)
|
2014-08-12 |
2017-06-30 |
Новартис Аг |
Конъюгаты анти-cdh6 антитела с лекарственным средством
|
|
EP3191126B1
(en)
|
2014-09-13 |
2020-05-13 |
Novartis AG |
Combination therapies of alk inhibitors
|
|
EP3662903A3
(en)
|
2014-10-03 |
2020-10-14 |
Novartis AG |
Combination therapies
|
|
TW201625692A
(zh)
|
2014-11-14 |
2016-07-16 |
諾華公司 |
抗體藥物結合物
|
|
PL3230289T3
(pl)
*
|
2014-12-11 |
2020-03-31 |
Natco Pharma Limited |
Pochodne 7-(morfolinylo)-2-(n-piperazynylo)metylotieno[2, 3-c]pirydyny jako leki przeciwnowotworowe
|
|
CN108367003B
(zh)
|
2014-12-12 |
2022-01-21 |
麻省总医院 |
乳腺癌脑转移的治疗
|
|
EP3233918A1
(en)
|
2014-12-19 |
2017-10-25 |
Novartis AG |
Combination therapies
|
|
EA032416B1
(ru)
|
2014-12-23 |
2019-05-31 |
Новартис Аг |
Соединения триазолопиримидина и их применения
|
|
US10189813B2
(en)
|
2015-03-25 |
2019-01-29 |
Novartis Ag |
Formylated N-heterocyclic derivatives as FGFR4 inhibitors
|
|
AR104068A1
(es)
|
2015-03-26 |
2017-06-21 |
Hoffmann La Roche |
Combinaciones de un compuesto inhibidor de fosfoinosítido 3-cinasa y un compuesto inhibidor de cdk4/6 para el tratamiento del cáncer
|
|
WO2016196373A2
(en)
|
2015-05-30 |
2016-12-08 |
Genentech, Inc. |
Methods of treating her2-positive metastatic breast cancer
|
|
WO2016205334A1
(en)
|
2015-06-16 |
2016-12-22 |
Vascular Strategies Llc |
Drug delivery and imaging chemical conjugate, formulations and methods of use thereof
|
|
US20190194315A1
(en)
|
2015-06-17 |
2019-06-27 |
Novartis Ag |
Antibody drug conjugates
|
|
ES2805232T3
(es)
|
2015-06-19 |
2021-02-11 |
Novartis Ag |
Compuestos y composiciones para inhibir la actividad de SHP2
|
|
EP3310779B1
(en)
|
2015-06-19 |
2019-05-08 |
Novartis AG |
Compounds and compositions for inhibiting the activity of shp2
|
|
ES2824576T3
(es)
|
2015-06-19 |
2021-05-12 |
Novartis Ag |
Compuestos y composiciones para inhibir la actividad de SHP2
|
|
AU2016287189A1
(en)
|
2015-06-29 |
2017-10-12 |
F. Hoffmann-La Roche Ag |
Methods of treatment with taselisib
|
|
CN105147696A
(zh)
*
|
2015-07-08 |
2015-12-16 |
李荣勤 |
联合使用盐酸二甲双胍和gdc0941的抗乳腺癌颗粒剂及制备方法
|
|
GB201514760D0
(en)
*
|
2015-08-19 |
2015-09-30 |
Karus Therapeutics Ltd |
Compounds and method of use
|
|
MX2018003292A
(es)
|
2015-09-21 |
2018-08-01 |
Aptevo Res & Development Llc |
Polipéptidos de unión a cd3.
|
|
CN108430515B
(zh)
|
2015-10-29 |
2021-11-12 |
诺华股份有限公司 |
包含toll-样受体激动剂的抗体缀合物
|
|
WO2017087280A1
(en)
|
2015-11-16 |
2017-05-26 |
Genentech, Inc. |
Methods of treating her2-positive cancer
|
|
CA3006419A1
(en)
|
2015-12-03 |
2017-06-08 |
Novartis Ag |
Treatment of cancer with a pi3k inhibitor in a patient preselected for having a pik3ca mutation in the ctdna
|
|
CA3023032A1
(en)
|
2016-05-04 |
2017-11-09 |
Genoscience Pharma |
Substituted 2,4-diamino-quinoline derivatives for use in the treatment of proliferative diseases
|
|
CN109415360B
(zh)
|
2016-06-14 |
2021-11-02 |
诺华股份有限公司 |
用于抑制shp2活性的化合物和组合物
|
|
US10676479B2
(en)
|
2016-06-20 |
2020-06-09 |
Novartis Ag |
Imidazolepyridine compounds and uses thereof
|
|
EP3472168B1
(en)
|
2016-06-20 |
2024-01-10 |
Novartis AG |
Crystalline forms of triazolopyrimidine compound
|
|
WO2017221092A1
(en)
|
2016-06-20 |
2017-12-28 |
Novartis Ag |
Triazolopyridine compounds and uses thereof
|
|
TW201815787A
(zh)
|
2016-09-23 |
2018-05-01 |
美商基利科學股份有限公司 |
磷脂醯肌醇3-激酶抑制劑
|
|
TW201825465A
(zh)
|
2016-09-23 |
2018-07-16 |
美商基利科學股份有限公司 |
磷脂醯肌醇3-激酶抑制劑
|
|
TW201813963A
(zh)
|
2016-09-23 |
2018-04-16 |
美商基利科學股份有限公司 |
磷脂醯肌醇3-激酶抑制劑
|
|
CA3035080A1
(en)
|
2016-09-27 |
2018-04-05 |
Cero Therapeutics, Inc. |
Chimeric engulfment receptor molecules
|
|
KR102607967B1
(ko)
|
2016-12-19 |
2023-11-29 |
메르크 파텐트 게엠베하 |
단백질 키나제 억제제 및 추가 화학요법제의 조합물
|
|
NZ754994A
(en)
|
2016-12-22 |
2022-12-23 |
Amgen Inc |
Benzisothiazole, isothiazolo[3,4-b]pyridine, quinazoline, phthalazine, pyrido[2,3-d]pyridazine and pyrido[2,3-d]pyrimidine derivatives as kras g12c inhibitors for treating lung, pancreatic or colorectal cancer
|
|
JP6914336B2
(ja)
|
2016-12-28 |
2021-08-04 |
ジェネンテック， インコーポレイテッド |
進行したｈｅｒ２発現がんの治療
|
|
CN117752782A
(zh)
|
2017-01-17 |
2024-03-26 |
豪夫迈·罗氏有限公司 |
皮下her2抗体配制剂
|
|
JOP20190187A1
(ar)
|
2017-02-03 |
2019-08-01 |
Novartis Ag |
مترافقات عقار جسم مضاد لـ ccr7
|
|
CN116531511A
(zh)
|
2017-03-02 |
2023-08-04 |
豪夫迈·罗氏有限公司 |
Her2阳性乳腺癌的辅助治疗
|
|
US11179413B2
(en)
|
2017-03-06 |
2021-11-23 |
Novartis Ag |
Methods of treatment of cancer with reduced UBB expression
|
|
WO2018185618A1
(en)
|
2017-04-03 |
2018-10-11 |
Novartis Ag |
Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment
|
|
CN110536969A
(zh)
|
2017-04-24 |
2019-12-03 |
豪夫迈·罗氏有限公司 |
跨膜或近膜域中的erbb2/her2突变
|
|
AR111651A1
(es)
|
2017-04-28 |
2019-08-07 |
Novartis Ag |
Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
|
|
JOP20190272A1
(ar)
|
2017-05-22 |
2019-11-21 |
Amgen Inc |
مثبطات kras g12c وطرق لاستخدامها
|
|
CN111107868A
(zh)
|
2017-05-24 |
2020-05-05 |
诺华股份有限公司 |
抗体细胞因子移植蛋白及使用方法
|
|
WO2018215937A1
(en)
|
2017-05-24 |
2018-11-29 |
Novartis Ag |
Interleukin-7 antibody cytokine engrafted proteins and methods of use in the treatment of cancer
|
|
IL322309A
(en)
|
2017-05-24 |
2025-09-01 |
Novartis Ag |
IL2 antibody grafted proteins and methods of use in cancer treatment
|
|
US11459306B2
(en)
|
2017-07-31 |
2022-10-04 |
The Trustees Of Columbia University In The City Of New York |
Compounds, compositions, and methods for treating T-cell acute lymphoblastic leukemia
|
|
JP2020530000A
(ja)
*
|
2017-08-02 |
2020-10-15 |
ノースウエスタン ユニバーシティ |
置換縮合ピリミジン化合物およびその使用
|
|
ES2928576T3
(es)
|
2017-09-08 |
2022-11-21 |
Amgen Inc |
Inhibidores de KRAS G12C y métodos de uso de los mismos
|
|
TW202517628A
(zh)
|
2017-09-11 |
2025-05-01 |
美商克魯松藥物公司 |
Shp2之八氫環戊烷并[c]吡咯別構抑制劑
|
|
JP7286658B2
(ja)
|
2017-09-26 |
2023-06-05 |
セロ・セラピューティクス・インコーポレイテッド |
キメラエンガルフメント受容体分子および使用方法
|
|
CN108187055B
(zh)
*
|
2018-03-06 |
2019-12-27 |
北京大学 |
一种具有协同增效作用的抗癌组合物
|
|
AU2019243154A1
(en)
|
2018-03-28 |
2020-10-01 |
Cero Therapeutics, Inc. |
Cellular immunotherapy compositions and uses thereof
|
|
WO2019191339A1
(en)
|
2018-03-28 |
2019-10-03 |
Cero Therapeutics, Inc. |
Expression vectors for chimeric engulfment receptors, genetically modified host cells, and uses thereof
|
|
EP3774906A1
(en)
|
2018-03-28 |
2021-02-17 |
Cero Therapeutics, Inc. |
Chimeric tim4 receptors and uses thereof
|
|
EP3773591A4
(en)
|
2018-04-05 |
2021-12-22 |
Sumitomo Dainippon Pharma Oncology, Inc. |
AXL KINASE INHIBITORS AND THEIR USE
|
|
MA52501A
(fr)
|
2018-05-04 |
2021-03-10 |
Amgen Inc |
Inhibiteurs de kras g12c et leurs procédés d'utilisation
|
|
CA3099118A1
(en)
|
2018-05-04 |
2019-11-07 |
Amgen Inc. |
Kras g12c inhibitors and methods of using the same
|
|
EP3790886B1
(en)
|
2018-05-10 |
2024-06-26 |
Amgen Inc. |
Kras g12c inhibitors for the treatment of cancer
|
|
EP3802535B1
(en)
|
2018-06-01 |
2022-12-14 |
Amgen, Inc |
Kras g12c inhibitors and methods of using the same
|
|
CA3099799A1
(en)
|
2018-06-11 |
2019-12-19 |
Amgen Inc. |
Kras g12c inhibitors for treating cancer
|
|
MA51848A
(fr)
|
2018-06-12 |
2021-04-21 |
Amgen Inc |
Inhibiteurs de kras g12c et leurs procédés d'utilisation
|
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
|
BR122022012697B1
(pt)
|
2018-07-10 |
2023-04-04 |
Novartis Ag |
Usos de derivados de 3-(5-hidróxi-1-oxoisoindolin-2-il)piperidina-2,6- diona, e kit
|
|
CA3103995A1
(en)
|
2018-07-26 |
2020-01-30 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Methods for treating diseases associated with abnormal acvr1 expression and acvr1 inhibitors for use in the same
|
|
EP4219488A1
(en)
|
2018-08-17 |
2023-08-02 |
Novartis AG |
Method for the preparation of urea compounds as smarca2/brm-atpase inhibitors
|
|
CN113164466B
(zh)
|
2018-09-11 |
2025-07-08 |
柯瑞斯公司 |
使用具有锌结合部分的磷酸肌醇3-激酶抑制剂的联合治疗
|
|
CN112996795B
(zh)
|
2018-09-18 |
2024-11-12 |
尼坎治疗公司 |
作为src同源-2磷酸酶抑制剂的稠合的三环衍生物
|
|
JP2022502496A
(ja)
|
2018-09-25 |
2022-01-11 |
ブラック ダイアモンド セラピューティクス，インコーポレイティド |
チロシンキナーゼ阻害剤組成物、作製方法、および使用方法
|
|
WO2020068867A1
(en)
|
2018-09-25 |
2020-04-02 |
Black Diamond Therapeutics, Inc. |
Quinazoline derivatives as tyrosine kinase inhibitor, compositions, methods of making them and their use
|
|
IL305106B2
(en)
|
2018-09-29 |
2025-08-01 |
Novartis Ag |
Process of manufacture of a compound for inhibiting the activity of shp2
|
|
US20230053449A1
(en)
|
2018-10-31 |
2023-02-23 |
Novartis Ag |
Dc-sign antibody drug conjugates
|
|
JP7516029B2
(ja)
|
2018-11-16 |
2024-07-16 |
アムジエン・インコーポレーテツド |
Ｋｒａｓ ｇ１２ｃ阻害剤化合物の重要な中間体の改良合成法
|
|
US11053226B2
(en)
|
2018-11-19 |
2021-07-06 |
Amgen Inc. |
KRAS G12C inhibitors and methods of using the same
|
|
JP7377679B2
(ja)
|
2018-11-19 |
2023-11-10 |
アムジエン・インコーポレーテツド |
がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
|
|
AU2019401495B2
(en)
|
2018-12-20 |
2025-06-26 |
Amgen Inc. |
Heteroaryl amides useful as KIF18A inhibitors
|
|
MX2021007392A
(es)
|
2018-12-20 |
2021-08-24 |
Novartis Ag |
Regimen de dosificacion y combinacion farmaceutica que comprende derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona.
|
|
MA54550A
(fr)
|
2018-12-20 |
2022-03-30 |
Amgen Inc |
Inhibiteurs de kif18a
|
|
MA54546A
(fr)
|
2018-12-20 |
2022-03-30 |
Amgen Inc |
Amides d'hétéroaryle utiles en tant qu'inhibiteurs de kif18a
|
|
EA202191730A1
(ru)
|
2018-12-20 |
2021-08-24 |
Эмджен Инк. |
Ингибиторы kif18a
|
|
KR20240052881A
(ko)
|
2018-12-21 |
2024-04-23 |
노파르티스 아게 |
Pmel17에 대한 항체 및 이의 접합체
|
|
EP3908577A4
(en)
*
|
2019-01-11 |
2022-06-29 |
The Board of Trustees of the Leland Stanford Junior University |
Pi4-kinase inhibitors with anti-cancer activity
|
|
NZ778055A
(en)
|
2019-02-12 |
2025-11-28 |
Sumitomo Pharma America Inc |
Formulations comprising heterocyclic protein kinase inhibitors
|
|
WO2020165834A1
(en)
|
2019-02-15 |
2020-08-20 |
Novartis Ag |
Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
BR112021015783A2
(pt)
|
2019-02-15 |
2021-10-05 |
Novartis Ag |
Derivados de 3-(1-oxo-5-(piperidin-4-il)isoindolin-2-il)piperidina-2,6-diona e usos dos mesmos
|
|
KR20210146287A
(ko)
|
2019-03-01 |
2021-12-03 |
레볼루션 메디슨즈, 인크. |
이환식 헤테로아릴 화합물 및 이의 용도
|
|
CN113727758A
(zh)
|
2019-03-01 |
2021-11-30 |
锐新医药公司 |
双环杂环基化合物及其用途
|
|
US12415788B2
(en)
|
2019-03-21 |
2025-09-16 |
The Board Of Trustees Of The Leland Stanford Junior University |
PI4-kinase inhibitors and methods of using the same
|
|
WO2020198077A1
(en)
|
2019-03-22 |
2020-10-01 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Compositions comprising pkm2 modulators and methods of treatment using the same
|
|
EP3738593A1
(en)
|
2019-05-14 |
2020-11-18 |
Amgen, Inc |
Dosing of kras inhibitor for treatment of cancers
|
|
EP3972973A1
(en)
|
2019-05-21 |
2022-03-30 |
Amgen Inc. |
Solid state forms
|
|
CN114302878A
(zh)
|
2019-07-03 |
2022-04-08 |
大日本住友制药肿瘤公司 |
酪氨酸激酶非受体1(tnk1)抑制剂及其用途
|
|
JP7640521B2
(ja)
|
2019-08-02 |
2025-03-05 |
アムジエン・インコーポレーテツド |
Ｋｉｆ１８ａ阻害剤として有用なヘテロアリールアミド
|
|
WO2021026098A1
(en)
|
2019-08-02 |
2021-02-11 |
Amgen Inc. |
Kif18a inhibitors
|
|
CN114391012B
(zh)
|
2019-08-02 |
2025-10-31 |
美国安进公司 |
作为kif18a抑制剂的吡啶衍生物
|
|
ES3051918T3
(en)
|
2019-08-02 |
2025-12-30 |
Amgen Inc |
Kif18a inhibitors
|
|
WO2021030711A1
(en)
|
2019-08-15 |
2021-02-18 |
Black Diamond Therapeutics, Inc. |
Alkynyl quinazoline compounds
|
|
WO2021055728A1
(en)
|
2019-09-18 |
2021-03-25 |
Merck Sharp & Dohme Corp. |
Small molecule inhibitors of kras g12c mutant
|
|
CN114746414B
(zh)
|
2019-09-26 |
2024-10-18 |
诺华公司 |
氮杂-喹啉化合物及其用途
|
|
WO2021067875A1
(en)
|
2019-10-03 |
2021-04-08 |
Cero Therapeutics, Inc. |
Chimeric tim4 receptors and uses thereof
|
|
EP4045047A1
(en)
|
2019-10-15 |
2022-08-24 |
Amgen Inc. |
Combination therapy of kras inhibitor and shp2 inhibitor for treatment of cancers
|
|
EP4048671B1
(en)
|
2019-10-24 |
2026-03-18 |
Amgen Inc. |
Pyridopyrimidine derivatives useful as kras g12c and kras g12d inhibitors in the treatment of cancer
|
|
CR20220230A
(es)
|
2019-10-28 |
2022-06-15 |
Merck Sharp & Dohme |
Inhibidores de pequeñas moléculas de mutante g12c de kras
|
|
WO2021085653A1
(en)
|
2019-10-31 |
2021-05-06 |
Taiho Pharmaceutical Co., Ltd. |
4-aminobut-2-enamide derivatives and salts thereof
|
|
KR20220109407A
(ko)
|
2019-11-04 |
2022-08-04 |
레볼루션 메디슨즈, 인크. |
Ras 억제제
|
|
EP4054719B1
(en)
|
2019-11-04 |
2026-02-11 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
JP7823816B2
(ja)
|
2019-11-04 |
2026-03-04 |
レヴォリューション・メディスンズ，インコーポレイテッド |
Ｒａｓ阻害剤
|
|
BR112022008858A2
(pt)
|
2019-11-08 |
2022-09-06 |
Revolution Medicines Inc |
Composto, composição farmacêutica e métodos para inibir sos1 em um sujeito, para inibir a interação de sos1 e uma proteína, para tratar ou prevenir uma doença e para tratar ou prevenir câncer
|
|
JP2023501528A
(ja)
|
2019-11-14 |
2023-01-18 |
アムジエン・インコーポレーテツド |
Ｋｒａｓ ｇ１２ｃ阻害剤化合物の改善された合成
|
|
WO2021097207A1
(en)
|
2019-11-14 |
2021-05-20 |
Amgen Inc. |
Improved synthesis of kras g12c inhibitor compound
|
|
WO2021108683A1
(en)
|
2019-11-27 |
2021-06-03 |
Revolution Medicines, Inc. |
Covalent ras inhibitors and uses thereof
|
|
WO2021106231A1
(en)
|
2019-11-29 |
2021-06-03 |
Taiho Pharmaceutical Co., Ltd. |
A compound having inhibitory activity against kras g12d mutation
|
|
US20230028414A1
(en)
|
2019-12-16 |
2023-01-26 |
Amgen Inc. |
Dosing regimen of kras g12c inhibitor
|
|
TW202135859A
(zh)
|
2019-12-20 |
2021-10-01 |
瑞士商諾華公司 |
組合療法
|
|
CN111057065B
(zh)
*
|
2019-12-24 |
2021-04-23 |
沈阳药科大学 |
噻吩并嘧啶类化合物的制备方法和用途
|
|
CN114929279A
(zh)
|
2020-01-07 |
2022-08-19 |
锐新医药公司 |
Shp2抑制剂给药和治疗癌症的方法
|
|
WO2021195206A1
(en)
|
2020-03-24 |
2021-09-30 |
Black Diamond Therapeutics, Inc. |
Polymorphic forms and related uses
|
|
WO2021215545A1
(en)
|
2020-04-24 |
2021-10-28 |
Taiho Pharmaceutical Co., Ltd. |
Anticancer combination therapy with n-(1-acryloyl-azetidin-3-yl)-2-((1h-indazol-3-yl)amino)methyl)-1h-imidazole-5-carboxamide inhibitor of kras-g12c
|
|
US20230174518A1
(en)
|
2020-04-24 |
2023-06-08 |
Taiho Pharmaceutical Co., Ltd. |
Kras g12d protein inhibitors
|
|
US20230181756A1
(en)
|
2020-04-30 |
2023-06-15 |
Novartis Ag |
Ccr7 antibody drug conjugates for treating cancer
|
|
EP4161519A4
(en)
*
|
2020-06-03 |
2024-07-17 |
Yumanity Therapeutics, Inc. |
PURINES AND METHODS OF USE
|
|
KR20230024967A
(ko)
|
2020-06-11 |
2023-02-21 |
노파르티스 아게 |
Zbtb32 억제제 및 이의 용도
|
|
WO2021260528A1
(en)
|
2020-06-23 |
2021-12-30 |
Novartis Ag |
Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
|
|
KR20250151568A
(ko)
|
2020-06-29 |
2025-10-21 |
제넨테크, 인크. |
퍼투주맙 + 트라스투주맙 고정 용량 조합
|
|
EP4183395A4
(en)
|
2020-07-15 |
2024-07-24 |
Taiho Pharmaceutical Co., Ltd. |
PYRIMIDINE COMPOUND-CONTAINING COMBINATION FOR USE IN TUMOR TREATMENT
|
|
JP7819176B2
(ja)
|
2020-08-03 |
2026-02-24 |
ノバルティス アーゲー |
ヘテロアリール置換３－（１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用
|
|
AR123185A1
(es)
|
2020-08-10 |
2022-11-09 |
Novartis Ag |
Compuestos y composiciones para inhibir ezh2
|
|
WO2022036265A1
(en)
|
2020-08-14 |
2022-02-17 |
Cero Therapeutics, Inc. |
Chimeric tim receptors and uses thereof
|
|
WO2022036287A1
(en)
|
2020-08-14 |
2022-02-17 |
Cero Therapeutics, Inc. |
Anti-cd72 chimeric receptors and uses thereof
|
|
WO2022036285A1
(en)
|
2020-08-14 |
2022-02-17 |
Cero Therapeutics, Inc. |
Compositions and methods for treating cancer with chimeric tim receptors in combination with inhibitors of poly (adp-ribose) polymerase
|
|
US20230338587A1
(en)
|
2020-08-31 |
2023-10-26 |
Advanced Accelerator Applications International Sa |
Method of treating psma-expressing cancers
|
|
WO2022043557A1
(en)
|
2020-08-31 |
2022-03-03 |
Advanced Accelerator Applications International Sa |
Method of treating psma-expressing cancers
|
|
WO2022043556A1
(en)
|
2020-08-31 |
2022-03-03 |
Novartis Ag |
Stable radiopharmaceutical composition
|
|
MX2023002248A
(es)
|
2020-09-03 |
2023-05-16 |
Revolution Medicines Inc |
Uso de inhibidores de sos1 para tratar neoplasias malignas con mutaciones de shp2.
|
|
CR20230165A
(es)
|
2020-09-15 |
2023-06-02 |
Revolution Medicines Inc |
Derivados indólicos como inhibidores de ras en el tratamiento del cáncer
|
|
US11685744B2
(en)
|
2020-09-21 |
2023-06-27 |
Prelude Therapeutics Incorporated |
CDK inhibitors and their use as pharmaceuticals
|
|
TW202237638A
(zh)
|
2020-12-09 |
2022-10-01 |
日商武田藥品工業股份有限公司 |
烏苷酸環化酶ｃ（ｇｃｃ）抗原結合劑之組成物及其使用方法
|
|
TW202237119A
(zh)
|
2020-12-10 |
2022-10-01 |
美商住友製藥腫瘤公司 |
Ａｌｋ﹘５抑制劑和彼之用途
|
|
CN117396472A
(zh)
|
2020-12-22 |
2024-01-12 |
上海齐鲁锐格医药研发有限公司 |
Sos1抑制剂及其用途
|
|
WO2022135346A1
(en)
*
|
2020-12-22 |
2022-06-30 |
Novartis Ag |
Pharmaceutical combinations comprising a kras g12c inhibitor and uses of a kras g12c inhibitor for the treatment of cancers
|
|
WO2022140472A1
(en)
|
2020-12-22 |
2022-06-30 |
Nikang Therapeutics, Inc. |
Compounds for degrading cyclin-dependent kinase 2 via ubiquitin proteosome pathway
|
|
WO2022170052A1
(en)
|
2021-02-05 |
2022-08-11 |
Black Diamond Therapeutics, Inc. |
Quinazoline derivatives, pyridopyrimidine derivatives, pyrimidopyrimidine derivatives, and uses thereof
|
|
IL305411A
(en)
|
2021-02-26 |
2023-10-01 |
Kelonia Therapeutics Inc |
Lymphocyte-targeted lentiviral vectors
|
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
|
|
US12037346B2
(en)
|
2021-04-13 |
2024-07-16 |
Nuvalent, Inc. |
Amino-substituted heteroaryls for treating cancers with EGFR mutations
|
|
CA3216880A1
(en)
|
2021-04-16 |
2022-10-20 |
Novartis Ag |
Antibody drug conjugates and methods for making thereof
|
|
CR20230558A
(es)
|
2021-05-05 |
2024-01-24 |
Revolution Medicines Inc |
Inhibidores de ras para el tratamiento del cáncer
|
|
IL308193A
(en)
|
2021-05-05 |
2024-01-01 |
Revolution Medicines Inc |
RAS inhibitors
|
|
WO2022235866A1
(en)
|
2021-05-05 |
2022-11-10 |
Revolution Medicines, Inc. |
Covalent ras inhibitors and uses thereof
|
|
AR125874A1
(es)
|
2021-05-18 |
2023-08-23 |
Novartis Ag |
Terapias de combinación
|
|
CN117769554A
(zh)
|
2021-05-28 |
2024-03-26 |
大鹏药品工业株式会社 |
Kras突变蛋白的小分子抑制剂
|
|
WO2023284730A1
(en)
|
2021-07-14 |
2023-01-19 |
Nikang Therapeutics, Inc. |
Alkylidene derivatives as kras inhibitors
|
|
US20250127896A1
(en)
|
2021-07-28 |
2025-04-24 |
Cero Therapeutics Holdings, Inc. |
Chimeric tim4 receptors and uses thereof
|
|
AR127308A1
(es)
|
2021-10-08 |
2024-01-10 |
Revolution Medicines Inc |
Inhibidores ras
|
|
WO2023064058A1
(en)
|
2021-10-12 |
2023-04-20 |
Peloton Therapeutics Inc. |
Tricyclic sultams and sulfamides as antitumor agents
|
|
JP2025500878A
(ja)
|
2021-12-17 |
2025-01-15 |
ジェンザイム・コーポレーション |
Ｓｈｐ２阻害剤としてのピラゾロピラジン化合物
|
|
EP4227307A1
(en)
|
2022-02-11 |
2023-08-16 |
Genzyme Corporation |
Pyrazolopyrazine compounds as shp2 inhibitors
|
|
IL314883A
(en)
|
2022-03-07 |
2024-10-01 |
Amgen Inc |
A process for preparing 4-methyl-2-propan-2-yl-pyridine-3-carbonitrile
|
|
CN119136806A
(zh)
|
2022-03-08 |
2024-12-13 |
锐新医药公司 |
用于治疗免疫难治性肺癌的方法
|
|
IL315603A
(en)
|
2022-03-28 |
2024-11-01 |
Nikang Therapeutics Inc |
Sulfonamido derivatives as cycle-dependent KINASE 2 inhibitors
|
|
WO2023214325A1
(en)
|
2022-05-05 |
2023-11-09 |
Novartis Ag |
Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
|
|
EP4536363A1
(en)
|
2022-06-08 |
2025-04-16 |
Nikang Therapeutics, Inc. |
Sulfamide derivatives as cyclin-dependent kinase 2 inhibitors
|
|
WO2023240263A1
(en)
|
2022-06-10 |
2023-12-14 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|
|
AU2023314354A1
(en)
|
2022-07-26 |
2024-11-21 |
Novartis Ag |
Crystalline forms of an akr1c3 dependent kars inhibitor
|
|
PE20251879A1
(es)
|
2022-10-14 |
2025-07-22 |
Black Diamond Therapeutics Inc |
Metodos de tratamiento del cancer usando derivados de isoquinolina o 6-aza-quinolina
|
|
TW202434563A
(zh)
|
2022-11-11 |
2024-09-01 |
美商尼坎醫療公司 |
用於經由泛素蛋白酶體途徑降解週期蛋白依賴性激酶２的含有２，５－取代的嘧啶衍生物之雙功能化合物
|
|
AU2024241633A1
(en)
|
2023-03-30 |
2025-11-06 |
Revolution Medicines, Inc. |
Compositions for inducing ras gtp hydrolysis and uses thereof
|
|
PE20260039A1
(es)
|
2023-04-07 |
2026-01-09 |
Revolution Medicines Inc |
Inhibidores macrociclicos de ras
|
|
WO2024211663A1
(en)
|
2023-04-07 |
2024-10-10 |
Revolution Medicines, Inc. |
Condensed macrocyclic compounds as ras inhibitors
|
|
TW202448897A
(zh)
|
2023-04-14 |
2024-12-16 |
美商銳新醫藥公司 |
Ｒａｓ抑制劑之結晶形式、含有其之組合物及其使用方法
|
|
CN121100123A
(zh)
|
2023-04-14 |
2025-12-09 |
锐新医药公司 |
Ras抑制剂的结晶形式
|
|
WO2024229406A1
(en)
|
2023-05-04 |
2024-11-07 |
Revolution Medicines, Inc. |
Combination therapy for a ras related disease or disorder
|
|
US20250049810A1
(en)
|
2023-08-07 |
2025-02-13 |
Revolution Medicines, Inc. |
Methods of treating a ras protein-related disease or disorder
|
|
TW202515582A
(zh)
|
2023-08-24 |
2025-04-16 |
日商大塚製藥股份有限公司 |
西區嘧啶(cedazuridine)之固定劑量組合
|
|
WO2025072462A1
(en)
|
2023-09-27 |
2025-04-03 |
Nikang Therapeutics, Inc. |
Sulfonamide derivatives as cyclin-dependent kinase 2 inhibitors
|
|
TW202530228A
(zh)
|
2023-10-12 |
2025-08-01 |
美商銳新醫藥公司 |
Ｒａｓ抑制劑
|
|
TW202535891A
(zh)
|
2023-10-20 |
2025-09-16 |
美商默沙東有限責任公司 |
Ｋｒａｓ蛋白之小分子抑制劑
|
|
WO2025117616A1
(en)
|
2023-11-27 |
2025-06-05 |
Nikang Therapeutics, Inc. |
Bifunctional compounds containing 2,5-substituted pyrimidine derivatives for degrading cyclin-dependent kinase 2 and cyclin-dependent kinase 4 via ubiquitin proteasome pathway
|
|
WO2025117981A1
(en)
|
2023-12-02 |
2025-06-05 |
Nikang Therapeutics, Inc. |
Bifunctional compounds containing 2,5-substituted pyrimidine derivatives for degrading cyclin-dependent kinase 2 via ubiquitin proteasome pathway
|
|
TW202542151A
(zh)
|
2023-12-22 |
2025-11-01 |
美商銳格醫藥有限公司 |
Ｓｏｓ１抑制劑及其用途
|
|
WO2025171296A1
(en)
|
2024-02-09 |
2025-08-14 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2025212828A1
(en)
|
2024-04-03 |
2025-10-09 |
Nikang Therapeutics, Inc. |
Bifunctional compounds containing 2,5-substituted pyrimidine derivatives for degrading cyclin-dependent kinase 2 and cyclin-dependent kinase 4 via ubiquitin proteasome pathway
|
|
WO2025240536A1
(en)
|
2024-05-15 |
2025-11-20 |
Nikang Therapeutics, Inc. |
Bifunctional compounds containing 2,5-substituted pyrimidine derivatives for degrading cyclin-dependent kinase 2 and/or cyclin-dependent kinase 4 via ubiquitin proteasome pathway
|
|
TW202547461A
(zh)
|
2024-05-17 |
2025-12-16 |
美商銳新醫藥公司 |
Ｒａｓ抑制劑
|
|
WO2025255438A1
(en)
|
2024-06-07 |
2025-12-11 |
Revolution Medicines, Inc. |
Methods of treating a ras protein-related disease or disorder
|
|
WO2025265060A1
(en)
|
2024-06-21 |
2025-12-26 |
Revolution Medicines, Inc. |
Therapeutic compositions and methods for managing treatment-related effects
|
|
WO2026006747A1
(en)
|
2024-06-28 |
2026-01-02 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026015796A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026015825A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Use of ras inhibitor for treating pancreatic cancer
|
|
WO2026015801A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026015790A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026050446A1
(en)
|
2024-08-29 |
2026-03-05 |
Revolution Medicines, Inc. |
Ras inhibitors
|